BioDelivery Sciences to Present at the 24th Annual Piper Jaffray
Healthcare Conference
RALEIGH, N.C., Nov. 19, 2012 /PRNewswire/ -- BioDelivery
Sciences International, Inc. (Nasdaq: BDSI) announced that Dr.
Mark A. Sirgo, President and Chief
Executive Officer of BDSI, will present at the 24th
Annual Piper Jaffray Healthcare Conference. The presentation
is scheduled for Tuesday, November 27,
2012 at 11:50 a.m. Eastern
Time, at The New York Palace in New York City.
(Logo:
http://photos.prnewswire.com/prnh/20110217/CL49801LOGO )
Dr. Sirgo will focus on the clinical development program and the
market opportunity for BEMA Buprenorphine/Naloxone (BNX) for the
treatment of opioid dependence, including the New Drug Application
(NDA) submission, which is anticipated to be submitted to the U.S.
Food and Drug Administration (FDA) in late second quarter of
2013. Additionally, Dr. Sirgo will discuss progress made by
BDSI and its commercial partner, Endo Health Solutions, with the
ongoing Phase 3 clinical studies for BEMA Buprenorphine for the
treatment of chronic pain.
The presentation will be webcast live and can be accessed at
www.bdsi.com. For those who are not available to listen to
the live broadcast, a replay of the webcast will be available on
the BDSI website.
About BioDelivery Sciences International
BioDelivery Sciences International (NASDAQ: BDSI) is a specialty
pharmaceutical company that is leveraging its novel and proprietary
patented drug delivery technologies to develop and commercialize,
either on its own or in partnerships with third parties, new
applications of proven therapeutics. BDSI is focusing on
developing products to meet unmet patient needs in the areas of
pain management and addiction. BDSI's pain franchise
currently consists of two products utilizing the patented BEMA
technology. ONSOLIS (fentanyl buccal soluble film) is
approved in the U.S., Canada, and
the E.U. (where it is marketed as BREAKYL), for the management of
breakthrough pain in opioid tolerant, adult patients with
cancer. The commercial rights are licensed to Meda for all
territories worldwide except for Taiwan (licensed to TTY Biopharm) and
South Korea (licensed to Kunwha
Pharmaceutical Co.). BDSI's second pain product, BEMA
Buprenorphine, is being developed for the treatment of moderate to
severe chronic pain and is licensed on a worldwide basis to Endo
Health Solutions. Additionally, BDSI is developing a high
dose formulation of buprenorphine in combination with naloxone
(BNX) for the treatment of opioid dependence. Both BEMA
Buprenorphine and BNX are in Phase 3 clinical development.
BDSI's headquarters is located in Raleigh, North Carolina. For more
information visit www.bdsi.com.
BDSI® and BEMA® are registered
trademarks of BioDelivery Sciences International, Inc.
ONSOLIS® is a registered trademark of Meda
Pharmaceuticals, Inc. BREAKYL™ is registered trademark of
Meda Pharma GmbH & Co. KG.
Cautionary Note on Forward-Looking Statements
This press release and any statements of representatives and
partners of BioDelivery Sciences International, Inc. (the
"Company") related thereto contain, or may contain, among other
things, certain "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve significant risks and
uncertainties. Such statements may include, without
limitation, statements with respect to the Company's plans,
objectives, projections, expectations and intentions and other
statements identified by words such as "projects," "may," "will,"
"could," "would," "should," "believes," "expects," "anticipates,"
"estimates," "intends," "plans," "potential" or similar
expressions. These statements are based upon the current
beliefs and expectations of the Company's management and are
subject to significant risks and uncertainties, including those
detailed in the Company's filings with the Securities and Exchange
Commission. Actual results (including, without limitation,
the results of the Company's 2012 and 2013 initiatives and
potential milestones described herein) may differ significantly
from those set forth in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the Company's control). The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
Readers are cautioned that peak sales and market size estimates
have been determined on the basis of market research and comparable
product analysis, but no assurances can be given that such
estimates are accurate or that such sales levels will be achieved,
if at all.
SOURCE BioDelivery Sciences International, Inc.